Navigation Links
Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease
Date:7/1/2008

A Complimentary Continuing Education Newsletter Series for Healthcare

Professionals

VOORHEES, N.J., July 1 /PRNewswire/ -- Clostridium difficile infection (CDI) is a serious condition that causes disease with a wide spectrum of severity, ranging from mild diarrhea to pseudomembranous colitis and death. Recurrent CDI can occur in up to 20% of patients who develop an initial case of CDI.(1) These patients are at increased risk of additional recurrences, as well as more complicated disease, including toxic megacolon, colon perforation, and systemic inflammatory response syndrome with organ failure leading to colectomy or death.

To address the need for education on recurrent CDI, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a 3-part series of complimentary educational newsletters targeted to primary care physicians. Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease is the first newsletter of this series.

The Expert Faculty for this continuing education activity include Ciaran P. Kelly, MD, Associate Professor of Medicine at Harvard Medical School, Director of Gastroenterology Fellowship Training at Beth Israel Deaconess Medical Center, and Chief of Hermann L. Blumgart Internal Medicine, and Vivian G. Loo, MD, MSc, FRCPC, Chief of the Department of Microbiology at McGill University Health Centre.

Healthcare professionals can receive this self-study activity by downloading or ordering online at http://www.rmei.com/CDInewsletters.

Healthcare professionals who treat patients with CDI should take advantage of this opportunity to learn about the management of patients with recurrent CDI.

This continuing education opportunity is jointly sponsored by Robert Michael Educational Institute LLC and Postgraduate Institute for Medicine and is supported by an educational grant from ViroPharma Incorporated.

Robert Michael Educational Institute LLC is a full-service medical education company dedicated to providing comprehensive medical education to healthcare providers, patients, and caregivers. Our mission is to design programs that improve diagnosis and treatment through a variety of educational programming such as national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs.

For other educational opportunities, please visit http://www.RMEI.com.

(1) McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999;20:43-50.


'/>"/>
SOURCE Robert Michael Educational Institute LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
3. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
4. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
5. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
6. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
7. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
8. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
9. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
10. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
11. APIC Launches Targeting Zero Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , February 23, 2017 The fast-growing ... the United States . According to the 2017 ... industry is expected to create 283,422 jobs by 2020, with ... over the next four years. The accelerating pace of cannabis ... growth of legal cannabis market, which will further create more ...
(Date:2/23/2017)... 2017 The top three players ... Healthcare, Koninklijke Philips N.V., and Schiller. Collectively, these companies ... market in 2015. Strong product portfolio and a monumental ... be aiding these players remain leaders in the fragmented ... in the global market are likely to focus on ...
(Date:2/23/2017)... Feb. 23, 2017   SeraCare Life Sciences ... in vitro diagnostics manufacturers and clinical laboratories, is ... Implementation of NGS-Based Tests" to be hosted by ... at 11am Eastern Standard Time (US). ... the need for improved performance and global standardization ...
Breaking Medicine Technology:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... publication and community for those in the fight against cancer, has produced a ... their success. HRA will release top-line findings in a webinar, Defining Compassionate ...
(Date:2/23/2017)... ... 2017 , ... CALNOC, the nation’s first and only nursing quality indicators database ... Empowerment, Value and Collaboration – in Seattle, WA on October 23, 2017. , Dr. ... System in Seattle since 2000. In addition to his role at Virginia Mason, Dr. ...
(Date:2/23/2017)... Minneapolis MN (PRWEB) , ... February 23, 2017 , ... ... it is sending an expert sit stand solutions representative to the Minneapolis Home and ... 5. Location for the event that is garnering national attention is the Minneapolis Convention ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... of a new healthcare contact center in Georgia, PENETRON Specialty Products (PSP) provided ... nation’s largest healthcare systems recently invested $51 million to purchase and renovate the ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy has made ... is so cutting edge, in fact, the U.S. Food and Drug Administration (FDA) ... successful patient outcomes in certain clinical stem cell procedures have shown that this ...
Breaking Medicine News(10 mins):